Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6467477

CCN(CCO)CCOc1ccc2nc(Nc3nc(C)c4cc(OC)cc(OC)c4n3)nc(O)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 2/20 0.36
MAPT P10636 4/20 0.35
KDM4E B2RXH2 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
PSMD14 O00487 1/20 0.35
APAF1 O14727 1/20 0.35
MITF O75030 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
PTK2B Q14289 1/20 0.35
USP2 O75604 2/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
TSHR P16473 1/20 0.33
TDP2 O95551 1/20 0.33
EGFR P00533 1/20 0.33
BRAF P15056 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6470895 0.96 MEN1 (0.37) MAPTKDM4EMEN1KMT2AALDH1A1
Trifluoroacetic Acid SCHEMBL6469701 0.91 KDM4E (0.35) MAPTKDM4EMEN1KMT2AALDH1A1
Trifluoroacetic Acid SCHEMBL6467347 0.90 FGFR2 (0.38) TLR7MAPTKDM4EMEN1KMT2A
Trifluoroacetic Acid SCHEMBL6467382 0.90 ALDH1A1 (0.38) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6469351 0.89 MEN1 (0.39) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL6467480 0.89 TLR7 (0.34) TLR7MAPTKDM4EMEN1KMT2A
Trifluoroacetic Acid SCHEMBL6467438 0.86 FGFR2 (0.41) MAPTKDM4EMEN1KMT2AALDH1A1
Trifluoroacetic Acid SCHEMBL6470080 0.86 KDM4E (0.39) MAPTKDM4EMEN1KMT2AALDH1A1
Trifluoroacetic Acid SCHEMBL6465761 0.86 AURKA (0.39) MAPTKDM4EMEN1KMT2AALDH1A1
Trifluoroacetic Acid SCHEMBL6467968 0.86 KDR (0.41) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB TLR7 1177/4885MAPT 3552/4885KDM4E 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.